In the published article, there was an error in Figure 2 as published. The blot quantification graph of Figure 2C was duplicated in place of the graph for Figure 2D. The corrected Figure 2 appears below.
Figure 2
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
corallocarpus epigaeus, cucurbitacin B, melanoma, apoptosis, NMR spectroscopy, mass spectrometry
Citation
Aiswarya SUD, Vikas G, Haritha NH, Liju VB, Shabna A, Swetha M, Rayginia TP, Keerthana CK, Nath LR, Reshma MV, Sundaram S, Anto NP, Lankalapalli RS, Anto RJ and Bava SV (2022) Corrigendum: Cucurbitacin B, purified and characterized from the rhizome of Corallocarpus epigaeus exhibits anti-melanoma potential. Front. Oncol. 12:989283. doi: 10.3389/fonc.2022.989283
Received
08 July 2022
Accepted
19 July 2022
Published
12 August 2022
Volume
12 - 2022
Edited and reviewed by
Balaji Krishnamachary, Johns Hopkins University, United States
Updates
Copyright
© 2022 Aiswarya, Vikas, Haritha, Liju, Shabna, Swetha, Rayginia, Keerthana, Nath, Reshma, Sundaram, Anto, Lankalapalli, Anto and Bava.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ravi Shankar Lankalapalli, ravishankar@niist.res.in; Ruby John Anto, rjanto@rgcb.res.in; Smitha Vadakkeveettil Bava, smithanishad@gmail.com
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.